PAR

Par Drugs & Chemicals Share Price

₹284.05 -5.3 (-1.83%)

21 Nov, 2024 14:21

SIP TrendupStart SIP in PAR

Start SIP

Performance

  • Low
  • ₹282
  • High
  • ₹291
  • 52 Week Low
  • ₹190
  • 52 Week High
  • ₹325
  • Open Price₹284
  • Previous Close₹289
  • Volume61,770

Investment Returns

  • Over 1 Month + 23.05%
  • Over 3 Month + 18.46%
  • Over 6 Month + 9.29%
  • Over 1 Year + 23.11%
SIP Lightning

Smart Investing Starts Here Start SIP with Par Drugs & Chemicals for Steady Growth!

Invest Now

Par Drugs & Chemicals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 19.1
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 350
  • P/B Ratio
  • 4.1
  • Average True Range
  • 18.7
  • EPS
  • 14.85
  • Dividend Yield
  • 0
  • MACD Signal
  • 10.5
  • RSI
  • 57.48
  • MFI
  • 61.19

Par Drugs & Chemicals Financials

Par Drugs & Chemicals Technicals

EMA & SMA

Current Price
₹284.05
-5.3 (-1.83%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹277.86
  • 50 Day
  • ₹263.57
  • 100 Day
  • ₹252.66
  • 200 Day
  • ₹240.40

Resistance and Support

285.4 Pivot Speed
  • R3 330.80
  • R2 314.35
  • R1 301.85
  • S1 272.90
  • S2 256.45
  • S3 243.95

What's your outlook on Par Drugs & Chemicals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Par Drugs and Chemicals has an operating revenue of Rs. 104.08 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 20% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 12% and 21% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 70 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Par Drugs & Chemicals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-22 Quarterly Results
2024-08-17 Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2024-08-03 Quarterly Results
2024-05-09 Audited Results & Others
2024-02-16 Quarterly Results (Revised) issue in the ratio of 1:1 of Rs. 10/-.
Date Purpose Remarks
2021-04-28 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Par Drugs & Chemicals F&O

Par Drugs & Chemicals Shareholding Pattern

73.37%
0.09%
19.42%
7.12%

About Par Drugs & Chemicals

  • NSE Symbol
  • PAR
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Falgun Vallabhbhai Savani
  • ISIN
  • INE04LG01015

Similar Stocks to Par Drugs & Chemicals

Par Drugs & Chemicals FAQs

Par Drugs & Chemicals share price is ₹284 As on 21 November, 2024 | 14:07

The Market Cap of Par Drugs & Chemicals is ₹349.5 Cr As on 21 November, 2024 | 14:07

The P/E ratio of Par Drugs & Chemicals is 19.1 As on 21 November, 2024 | 14:07

The PB ratio of Par Drugs & Chemicals is 4.1 As on 21 November, 2024 | 14:07

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23